Institute highlights include:

• Conducting multi-site randomized clinical trials, as a part of the National Institute on Drug Abuse (NIDA) Clinical Trials Network.
• Buprenorphine medically managed opiate withdrawal: Maryhaven participated in the first ever NIDA Clinical Trials Network Research Protocol, a multi-site randomized clinical trial that tested the effectiveness of Buprenorphine taper. The trial demonstrated this new treatment to be more than twice as effective at helping patients continue in treatment.
• Treating women with post-traumatic stress and substance abuse
• Effects of treating ADHD and tobacco smoking cessation
• Using 12 Step approaches for stimulant dependence
• Ongoing research for the development of new drug abuse treatments
• Research to understand how treatment organizations change and adopt new treatments
• Collaborating with Maryhaven’s array of treatment services to bring science based treatments into clinical practice.
• Active research and training collaborations with partners from around the country including:

–        Yale University School of Medicine

–        The Mayo Clinic

–        Johns Hopkins University

–        University of Cincinnati

–        The Ohio State University

–        University of California San Francisco

–        University of Georgia

–        University of New Mexico

–        University of Colorado